286836-02-0

Basic information

• Product Name: 1-bromo-2-(2,2-diethoxyethoxy)-4-methoxybenzene
• Synonyms: 1-bromo-2-(2,2-diethoxyethoxy)-4-methoxybenzene
• CAS NO: 286836-02-0
• Molecular Weight: 319.195
• Mol File: 286836-02-0.mol

Chemical Properties

• CAS DataBase Reference: 1-bromo-2-(2,2-diethoxyethoxy)-4-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-2-(2,2-diethoxyethoxy)-4-methoxybenzene(286836-02-0)
• EPA Substance Registry System: 1-bromo-2-(2,2-diethoxyethoxy)-4-methoxybenzene(286836-02-0)

Safety Data

• Hazardous Substances Data: 286836-02-0(Hazardous Substances Data)

Upstream product

• 63604-94-4 2-bromo-5-methoxyphenol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 150-19-6 O-methylresorcine 

Downstream Products

• 286836-01-9 7-bromo-4-methoxybenzofuran 

Relevant articles and documents

1,3-disubstituted ketene compound and application thereof

The invention relates to a 1,3-disubstituted ketene compound with a structure as shown in a formula (I) and application thereof. The compound mainly activates a PPAR (Peroxisome Proliferators-Activated Receptor) alpha, and also has excitation activity for PPPA delta and PPPA gamma. The 1,3-disubstituted ketene compound can be used for treating various diseases related to the PPAR regulation abnormality, such as NASH (nonalcoholic steatohepatitis), and particularly treating nonalcoholic hepatitis, also has potentials for treating diabetes, obesity, fibrotic diseases, cardiovascular diseases (comprising a heart failure, atherosclerosis and the like), kidney diseases (comprising chronic nephrosis, a kidney failure and the like), brain degenerative diseases (comprising the alzheimer disease and the like) and the like, and has higher application value. The formula is shown in the description.

TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS

1,2,4-Oxadiazol derivatives represented by formula (I) useful as sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated via S1P1 receptor are disclosed.

Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists

The present invention provides serotonergic aminoalkylbenzofurans of Formula (I): where R, R1, R2, R3, R4, R4′, R5, R5′, and R12 are as described in the specification.

SEROTONERGIC BENZOFURANS

The present invention provides serotonergic benzofurans of Formula (I): where A, R, R, R, R, and R are as described in the specification.

BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS

The present invention provides serotonergic benzofurylpiperazines of Formula I: where: A is a piperazine of formula: and R, R1, R2, R3, R4, R5, R5', R6, R6', R7, R7', R8, and R8' are as described in the specification.